- Home
- SVAC vs XFOR Comparison
SVAC vs XFOR Comparison
Compare SVAC & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$3.92
Company Overview
Basic Information| Metric | SVAC | XFOR |
|---|---|---|
| Founded | 2025 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 314.6M | 332.3M |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | SVAC | XFOR |
|---|---|---|
| Price | $10.28 | $3.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $28.50 |
| AVG Volume (30 Days) | 31.3K | ★ 614.3K |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $33,979,000.00 |
| Revenue This Year | N/A | $1,276.65 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2925.74 |
| 52 Week Low | $10.03 | $1.35 |
| 52 Week High | $10.89 | $26.83 |
Technical Indicators
Market Signals| Indicator | SVAC | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 56.22 |
| Support Level | N/A | $3.53 |
| Resistance Level | N/A | $4.07 |
| Average True Range (ATR) | 0.00 | 0.29 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 0.00 | 82.65 |
Price Performance
Historical Comparison SVAC
XFOR
About SVAC Spring Valley Acquisition Corp. III Class A Ordinary Shares
Spring Valley Acquisition Corp III is a blank check company.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.